SCHEMBL11027579

SCHEMBL11027579

CN1CCN(c2ccc(Nc3cc(Cc4c(F)cccc4F)cnc3C(N)=O)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 1/20 0.49
▸ CDK4 P11802 4/20 0.48
▸ CCND1 P24385 3/20 0.48
▸ CDK6 Q00534 3/20 0.48
▸ CCNT1 O60563 2/20 0.48
▸ CDK9 P50750 2/20 0.48
▸ CDK11A Q9UQ88 2/20 0.48
▸ JAK2 O60674 2/20 0.47
▸ JAK1 P23458 2/20 0.47
▸ TYK2 P29597 2/20 0.47
▸ JAK3 P52333 2/20 0.47
▸ PTK2 Q05397 1/20 0.47
▸ BTK Q06187 2/20 0.47
▸ FLT3 P36888 2/20 0.47
▸ STAT6 P42226 2/20 0.46
▸ EGFR P00533 1/20 0.46
▸ MAPKAPK2 P49137 2/20 0.44
▸ SYK P43405 2/20 0.44
▸ AURKA O14965 2/20 0.44
▸ CDK2 P24941 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11029039 0.94 JAK2 (0.52) SLC2A1CDK4CCND1CDK6CCNT1
SCHEMBL11033167 0.90 BTK (0.48) SLC2A1CDK4CCND1CDK6CCNT1
SCHEMBL11030740 0.89 SLC2A1 (0.55) SLC2A1CDK4CCND1CDK6CCNT1
SCHEMBL11028029 0.88 CDK4 (0.53) SLC2A1CDK4CCND1CDK6CCNT1
SCHEMBL11027886 0.87 SLC2A1 (0.47) SLC2A1CDK4CCND1CDK6CCNT1
SCHEMBL11027435 0.87 STAT6 (0.49) SLC2A1CDK4CCND1CDK6PTK2
SCHEMBL11028773 0.87 MAPKAPK2 (0.50) SLC2A1CDK4CCND1CDK6JAK1
SCHEMBL11025081 0.87 STAT6 (0.55) SLC2A1CDK4CCND1CDK6CCNT1
SCHEMBL11030732 0.85 NTRK1 (0.51) SLC2A1CDK4CCND1CDK6PTK2
SCHEMBL11029685 0.85 CSF1R (0.49) SLC2A1CDK4CCND1CDK6PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US claimed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP claimed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN claimed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO claimed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US claimed
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US disclosed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP disclosed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN disclosed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO disclosed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ALK, PKN2, ERBB2 SLC2A1 3662/4885CDK4 78/4885CCND1 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback